Ani Pharmaceuticals Inc. (ANIP) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Ani Pharmaceuticals’s revenue went from $129M in fiscal 2016 to $883M in fiscal 2025, growth of about 23.9% a year.
Net income in fiscal 2025 was $78M, a net margin of 8.9%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $1.0B and net income $117M.
Free cash flow was $171M in fiscal 2025 and positive in 9 of the 10 years shown.
The diluted share count rose 83% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $883M | $614M | $487M | $316M | $216M | $208M | $207M | $202M | $177M | $129M |
| Gross profit | — | — | — | — | — | — | $121M | $143M | $129M | $98M | $80M |
| Operating income | $166M | $111M | $584000 | $47M | -$35M | -$40M | -$16M | $16M | $35M | $28M | $20M |
| Net income | $117M | $78M | -$19M | $19M | -$48M | -$43M | -$23M | $6M | $15M | -$1M | $4M |
| EPS (diluted) | $5.01 | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 | $-1.88 | $0.50 | $1.30 | $-0.09 | $0.34 |
| R&D | $51M | $52M | $45M | $34M | $22M | $11M | $16M | $20M | $15M | $9M | $3M |
| Revenue growth | — | +43.8% | +26.2% | +53.9% | +46.4% | +3.7% | +0.9% | +2.5% | +14.0% | +37.5% | +68.5% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $229M | $185M | $64M | $119M | -$31M | $3M | $15M | $46M | $67M | $39M | $27M |
| Capital spending | -$24M | -$14M | -$16M | -$9M | -$9M | -$3M | -$6M | -$7M | -$6M | -$10M | -$5M |
| Free cash flow | $205M | $171M | $48M | $110M | -$40M | $765000 | $9M | $39M | $61M | $29M | $23M |
| Dividends paid | $0 | $1M | $2M | $2M | $2M | $190000 | $0 | $0 | — | — | — |
| Buybacks | $19M | $12M | $11M | $5M | $2M | $890000 | $2M | $1M | $0 | $0 | $2M |
| Stock-based pay | $43M | $38M | $29M | $21M | $15M | $10M | $13M | $9M | $7M | $6M | $6M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $286M | $145M | $221M | $48M | $100M | $8M | $62M | $43M | $31M | $27M |
| Debt | — | $320M | $324M | $291M | $289M | $289M | $186M | $186M | $71M | $128M | $121M |
| Equity | — | $541M | $404M | $433M | $314M | $334M | $196M | $213M | $197M | $175M | $170M |
| Total assets | — | $1.4B | $1.3B | $904M | $760M | $772M | $461M | $457M | $431M | $412M | $323M |
| Shares (diluted) | 22M | 21M | 19M | 18M | 16M | 13M | 12M | 12M | 12M | 12M | 12M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | 58.2% | 69.4% | 63.8% | 55.3% | 62.1% |
| Operating margin | 16.0% | 12.6% | 0.1% | 9.7% | -11.2% | -18.4% | -7.7% | 7.9% | 17.5% | 16.0% | 15.6% |
| Net margin | 11.2% | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% | -10.8% | 2.9% | 7.7% | -0.6% | 3.1% |
| FCF margin | 19.7% | 19.4% | 7.8% | 22.6% | -12.7% | 0.4% | 4.4% | 18.9% | 30.4% | 16.4% | 17.8% |
| ROIC | — | 10.5% | 0.1% | 6.1% | -4.5% | -4.9% | -3.6% | 3.2% | 10.2% | 7.4% | 5.5% |
| ROE | — | 14.5% | -4.6% | 4.3% | -15.3% | -12.8% | -11.5% | 2.9% | 7.8% | -0.6% | 2.3% |
Frequently asked questions
What is Ani Pharmaceuticals’s annual revenue?
$883M in fiscal 2025 and $1.0B over the twelve months to September 30, 2026.
How much profit does Ani Pharmaceuticals make?
Net income was $78M in fiscal 2025 (net margin 8.9%).
Is Ani Pharmaceuticals’s revenue growing?
Yes: revenue rose 43.8% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.